Basic Clinical Information on Cognitive Disorders

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 2013. 5th. ed. Washington, DC.

Argyriou AA, Assimakopoulos K, Iconomou G, et al.. Either called “chemobrain” or “chemofog,” the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symp Manage. 2011; 41: 126-39.

Bedillion MF, Ansell EB, Thomas GA. Cancer treatment effects on cognition and depression: The moderating role of physical activity. The Breast. 2019; 44: 73-80.

Cheung YT, Shwe M, Chui WK, et al. Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients. Ann Pharmacother. 2012; 46: 1645-55.

Durmaz B, Soysal P, Ellidokuz H, et al. Validity and reliability of geriatric depression scale-15 (short form) in Turkish older adults. Northern Clinics of Istanbul 2018; 5: 216.

El Majzoub I, Abunafeesa H, Cheaito R, et al. Management of altered mental status and delirium in cancer patients. Epidemiol. 2019; 14: 15.

Ertan T, Eker E, Şar V. Geriatrik depresyon ölçeğinin Türk yaşlı populasyonunda geçerlilik ve güvenilirliği. Nöropsikiyatri Arşivi 1997; 34: 62-71.

Galindo-Vazquez O, Vazquez-Rodriguez L, Bargallo-Rocha E, et al. Predicting factors of cognitive function, depression and anxiety in hispanic patients with breast cancer. J Clin Oncol. 2018; 36: e22162.

Greer JA, Park ER, Prigerson HG, et al. Tailoring cognitive-behavioral therapy to treat anxiety comorbid with advanced cancer. J Cogn Psychother. 2010; 24:294-313.

Hermelink K. Chemotherapy and cognitive function in breast cancer patients: the so-called chemo brain. J Nat Cancer Inst Monogr. 2015; 51: 67-9.

Hisli N. Beck depresyon envanterinin üniversite ögrencileri için geçerliliği,güvenilirliği (A reliability and validity study of Beck Depression Inventory in a university student sample). J Psychol. 1989; 7: 3-13.

Hormozi M, Hashemi SM, Shahraki S. Investigating relationship between pre-and post-chemotherapy cognitive performance with levels of depression and anxiety in breast cancer patients: A cross-sectional study. Asian Pac J Cancer Prev.2019; 20: 3831-7.

Jeffe DB, Naughton MJ, Weilbaecher KN, et al. Quality of life, depressed mood, and anxiety in women presenting with locally advanced breast cancer. J Clin Oncol.2004; 22: 8249.

Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006; 94: 828–34.

Karuturi M, Wong ML, Hsu T, et al. Understanding cognition in older patients with cancer. J Geriatr Oncol. 2016; 7: 258-69.

Keskinoglu P, Ucku R, Yener G, et al. Reliability and validity of revised Turkish version of Mini Mental State Examination (rMMSE‐T) in community‐dwelling educated and uneducated elderly. Int J Geriatr Psychiatry. 2009; 24: 1242-50.

Kesler SR, Blayney DW. Neurotoxic effects of anthracyclinevs nonanthracyclinebased chemotherapy on cognition in breast cancer survivors. JAMA Oncol.2016; 2: 185-92.

Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med.2000; 160: 786-94.

Magnuson A, Sattar S, Nightingale G, et al. A practical guide to geriatric syndromes in older adults with cancer: a focus on falls, cognition, polypharmacy,and depression. ASCO Educational Book. 2019; 39: e96-e109.

Mandilaras V, Wan-Chow-Wah D, Monette J, et al. The impact of cancer therapy on cognition in the elderly. Front Pharmacol. 2013; 4: 48.

Meyers C, Smith J, Bezjack A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004; 12:157–65.

Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment,MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc.2005; 53: 695-9.

Niedzwiedz CL, Knifton L, Robb KA, et al. Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority. BMC Cancer. 2019; 19: 1-8.

Selekler K, Congoz B, Uluc S. Power of discrimination of Montreal Cognitive Assessment (MoCA) Scale in Turkish patients with mild cognitive impairment and Alzheimer’s disease. Turk J Geriatr. 2010; 13: 166–71.

Shaw EG, Rosdhal R, D’Agostino RB Jr, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006; 24: 1415-20.

Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009; 27: 2758–65.

Sordillo PP, Sordillo LA. The mystery of chemotherapy brain: Kynurenines, tubulin and biophoton release. Anticancer Res. 2020; 40: 1189-200.Ulusoy M, Sahin NH, Erkmen H. The Beck Anxiety Inventory: sychometric

Ulusoy M, Sahin NH, Erkmen H. The Beck Anxiety Inventory: Psychometric Properties. J Cogn Psychother. 1998; 12: 163-72.

Vearncombe KJ, Rolfe M, Wright M, et al. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc. 2009; 15: 951-62.

Wefel JS, Lenzi R, Theriault R, et al. Chemobrain in breast carcinoma? A prologue. Cancer. 2004; 101: 466-75.

Wirkner J, Weymar M, Löw A, et al. Cognitive functioning and emotion processing in breast cancer survivors and controls: An ERP pilot study. Psychophysiol.2017; 54: 1209-22.

Yang Y, Hendrix CC. Cancer-related cognitive impairment in breast cancer patients:influences of psychological variables. Asia Pac J Oncol Nurs. 2018; 5:296.

Yavuz BB, Varan HD, O’Caoimh R, et al. Validation of the Turkish version of the quick mild cognitive impairment screen. Am J Alzheimers Dis Other Demen. 2017; 32: 145-56.

Yesavage JA, Brınk TL, Rose TL. Development and validation of geriatric depression screening scale: a preliminary report. J Psychiat Res. 1983; 17: 37-49.